A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-27. Anything still debated is marked as such rather than presented as settled.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
A tendon is a tough, flexible band of fibrous connective tissue that connects muscles to bones. The extra-cellular connective tissue between muscle fibers binds to tendons at the distal and proximal ends, and the tendon binds to the periosteum of individual bones at the muscle's origin and insertion. As muscles contract, tendons transmit the forces to the relatively rigid bones, pulling on them and causing movement. Tendons can stretch substantially, allowing them to function as springs during movement. Cartilage is a resilient and smooth type of connective tissue that covers and protects the ends of long bones, and forms a structural component of many body parts including the rib cage, the neck and the bronchial tubes, and the intervertebral discs. It is classified into three types — elastic cartilage, hyaline cartilage, and fibrocartilage. Joints, also known as articulations, are structures that connect individual bones and may allow bones to move against each other to cause movement. Joints can be classified by structure and by function. Structurally, synovial joints are joints that are not directly joined, which are lubricated by a solution called synovial fluid; fibrous, bony, and cartilaginous joints are characterised by the presence of their respective connective tissues. There are three functional divisions of joints: Diarthroses, which allow extensive mobility between two or more articular heads. Amphiarthroses, which allow some movement. False joints or synarthroses, which allow little or no movement and are predominantly fibrous.
In an early media report on MDMA published in 1982, a Drug Enforcement Administration (DEA) spokesman stated the agency would ban the drug if enough evidence for abuse could be found. By mid-1984, MDMA use was becoming more noticed. Bill Mandel reported on "Adam" in a 10 June San Francisco Chronicle article, but misidentified the drug as methyloxymethylenedioxyamphetamine (MMDA). In the next month, the World Health Organization identified MDMA as the only substance out of twenty phenethylamines to be seized a significant number of times. After a year of planning and data collection, MDMA was proposed for scheduling by the DEA on 27 July 1984, with a request for comments and objections. The DEA was surprised when a number of psychiatrists, psychotherapists, and researchers objected to the proposed scheduling and requested a hearing. In a Newsweek article published the next year, a DEA pharmacologist stated that the agency had been unaware of its use among psychiatrists. An initial hearing was held on 1 February 1985 at the DEA offices in Washington, D.C., with administrative law judge Francis L. Young presiding. It was decided there to hold three more hearings that year: Los Angeles on 10 June, Kansas City, Missouri on 10–11 July, and Washington, D.C., on 8–11 October. Sensational media attention was given to the proposed criminalization and the reaction of MDMA proponents, effectively advertising the drug.
Nearly all of our knowledge of Paleolithic people and way of life comes from archaeology and ethnographic comparisons to modern hunter-gatherer cultures such as the !Kung San who live similarly to their Paleolithic predecessors. The economy of a typical Paleolithic society was a hunter-gatherer economy. Humans hunted wild animals for meat and gathered food, firewood, and materials for their tools, clothes, or shelters. The population density was very low, around only 0.4 inhabitants per square kilometre (1/sq mi). This was most likely due to low body fat, infanticide, high levels of physical activity among women, late weaning of infants, and a nomadic lifestyle. In addition, even a large area of land could not support many people without being actively farmed – food was difficult to come by and so groups were prevented from growing too large by the amount of food they could gather. Like contemporary hunter-gatherers, Paleolithic humans enjoyed an abundance of leisure time unparalleled in both Neolithic farming societies and modern industrial societies. At the end of the Paleolithic, specifically the Middle or Upper Paleolithic, people began to produce works of art such as cave paintings, rock art and jewellery and began to engage in religious behavior such as burials and rituals.
==== Defence procurement ==== The Defence budget was protected by a NATO commitment to increase defence spending by 3% per annum until 1986, but was still subjected to cuts in the proposed budget during Heseltine's tenure. Some senior military figures felt that Heseltine was obsessed with the minutiae of running the department rather than thinking strategically about defence priorities and procurement. Dwin Bramall recalled that Heseltine never showed an interest in the strategy papers he sent him. Thatcher was highly critical of him for failing to take a decision on the development of the Nimrod early-warning plane, on which £660 million was spent over a ten-year period, only for the project to be cancelled by his successor. Some accusations were raised (the Commons Select Committee on Defence thought him "vague and evasive" on the issue in 1985) that the accounts were being massaged to push costs into the period after 1986, when cuts would become inevitable. The journalist Hugo Young later recalled Heseltine briefing journalists confidentially that spending and funding could be reconciled until 1986, by which time he expected "to be gone". In Cabinet, Heseltine resented being kept out of economic debates and suspected he might be reshuffled to the job of Secretary of State for Northern Ireland as Jim Prior had been. He had tried to pursue a one-man industrial policy, as defence spent £17 billion per annum, 5% of UK GDP, half of it on procurement, and 90% of that in the UK, with 700,000 British jobs dependent on it.
== Awards and recognition == David Rumbough Award for Scientific Achievement, Juvenile Diabetes Foundation (1977) Eli Lilly Award for Research, American Diabetes Association (1981) Cristobal Diaz Award for Research, International Diabetes Federation (1988) Banting Medal for Distinguished Scientific Achievement, American Diabetes Association (1993) Solomon Berson Distinguished Lecture, American Physiological Society (1997) Albert Renold Award, American Diabetes Association (1998) Dorothy Hodgkin Award, British Diabetes Association (1999) Fred Conrad Koch Award for Distinguished Contributions to Endocrinology, Endocrine Society (2000) Hamdan Award for Medical Research Excellence, awarded by Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, Dubai, United Arab Emirates (2000) Lawson Wilkins Award Lecture, Pediatric Endocrine Society (2001) Rolf Luft Award Lecture, Karolinska Institute, Stockholm, Sweden (2001) Steven C. Beering Award for Advancement of Biomedical Science, Indiana University (2002) J.
Sources: en.wikipedia.org
=== Border openings === Finally, at 22:45 (alternatively given as 23:30) on 9 November, Harald Jäger, commander of the Bornholmer Straße border crossing, yielded, allowing guards to open the checkpoints and let people through with little or no identity-checking. As the Ossis swarmed through, they were greeted by Wessis waiting with flowers and champagne amid wild rejoicing. Soon afterward, a crowd of West Berliners jumped on top of the Wall and were soon joined by East German youngsters. The evening of 9 November 1989 is known as the night the Wall came down.
=== Barney Calhoun === Barney Calhoun is the player character in Half-Life: Blue Shift and a major character in Half-Life 2 as well as Half-Life 2: Episode One. Michael Shapiro provided Barney's voice in the games of the Half-Life series. Scott Lynch, Valve's chief operating officer, lent his face to the game for use in-game as Barney in Half-Life 2. Barney's name stemmed from the earlier alpha versions of Half-Life in which the model for the security guards held a resemblance to actor Don Knotts, inspiring comparisons with Knotts's character Barney Fife from The Andy Griffith Show, which in the United States has long been a disparaging term for an inept policeman or security guard. Initially, the "Barneys" were intended to be hostile NPCs who would attack the player. In Half-Life: Blue Shift, the playable Barney progresses through Black Mesa to escape the events of the Resonance Cascade and is able to do so, in contrast to Gordon Freeman and Adrian Shephard, who are held in stasis. In Half-Life 2, Barney works as a mole for the Lambda Resistance in the Combine Civil Protection Forces. He provides the player information in the first chapter, leading him to Kleiner and Vance, and in the end of the second chapter, he provides the player with his crowbar. The fact that Barney owes Gordon Freeman a beer is a running gag in the series.
== Effects upon EU policy == The EU often applies the precautionary principle very stringently in regards to food safety. The precautionary principle means that in a case of scientific uncertainty, the government may take appropriate measures proportionate to the potential risk (EC Regulation 178/2002). In 1996, the EU banned imported beef from the US and continued to do so after the 2003 Mad Cow scare. A more sophisticated risk assessment found there to be insufficient risk to ban certain hormones, but continued to ban others. Labeling of meat was another option, however warnings were also insufficient because of the criteria specified in the SPS (Sanitary and Phyto-Sanitary agreement). This agreement allows members to use scientifically based measures to protect public health. Most specifically the Equivalence provision in Article 4 which states the following: "an importing country must accept an SPS measure which differs from its own as equivalent if the exporting country’s measure provides the same level of health or environmental protection." Therefore, although the EU is a strong proponent of labels and banning meat that contains growth hormones, requiring the US to do the same would have violated this agreement.
== Etymology == The word "lich" is derived from the Old English līċ, meaning "corpse". It is cognate with modern German Leiche, modern Danish lig, and modern Dutch lijk, all of which also mean "corpse".
Sources: en.wikipedia.org
Moscow has an extensive tram system, which opened in 1899. The newest line was constructed in 1984. Daily tram usage by Muscovites is low, making up approximately 5% of trips, because vital connections in the network have been phased out. Nevertheless, trams remain important in some districts as feeders to metro stations. Trams also provide important cross-links between metro lines—for example, between the Universitet station on the Sokolnicheskaya Line (#1 red line) and the Profsoyuznaya station on the Kaluzhsko-Rizhskaya Line (#6 orange line), and similarly between the Voykovskaya metro station and the Strogino metro station.
aeruginosa isolates requires several different genetic events, including acquisition of different mutations and/or horizontal transfer of antibiotic resistance genes. Hypermutation favours the selection of mutation-driven antibiotic resistance in P. aeruginosa strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in integrons favors the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown phenotypic resistance associated to biofilm formation or to the emergence of small-colony variants may be important in the response of P. aeruginosa populations to antibiotic treatment. Mechanisms underlying antibiotic resistance have been found to include production of antibiotic-degrading or antibiotic-inactivating enzymes, outer membrane proteins to evict the antibiotics, and mutations to change antibiotic targets. Presence of antibiotic-degrading enzymes such as extended-spectrum β-lactamases like PER-1, PER-2, and VEB-1, AmpC cephalosporinases, carbapenemases like serine oxacillinases, metallo-b-lactamases, OXA-type carbapenemases, and aminoglycoside-modifying enzymes, among others, have been reported. P. aeruginosa can also modify the targets of antibiotic action: for example, methylation of 16S rRNA to prevent aminoglycoside binding and modification of DNA, or topoisomerase to protect it from the action of quinolones. P.
Some conducting materials may pass electrons to form a difference in electrical charge at the joint. This results in a structure similar to a capacitor and creates an attractive electrostatic force between the materials.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.